Neuroscience Letters 1997-11-28

Effect of the cannabinoid receptor SPECT agent, AM 281, on hippocampal acetylcholine release from rat brain slices.

A N Gifford, Y Tang, S J Gatley, N D Volkow, R Lan, A Makriyannis

Index: Neurosci. Lett. 238 , 84-86, (1997)

Full Text: HTML

Abstract

The SPECT ligand AM 281, a less lipophilic analog of the cannabinoid receptor antagonist SR 141716A, robustly potentiated electrically-evoked release of acetylcholine from superfused hippocampal slices and prevented the inhibition of acetylcholine release by the cannabimimetic drug WIN 55212-2. These results, similar to earlier observations with SR 141716A, indicate that AM 281 is either a cannabinoid receptor antagonist or inverse agonist. Despite showing lower affinity than SR 141716A in hippocampal membrane binding experiments, AM 281 had slightly greater potency than SR 141716A in the hippocampal slice experiments, perhaps because of reduced drug absorption to slice membranes and to the apparatus.

Related Compounds

  • AM281

Related Articles:

Cannabinoid agonists rearrange synaptic vesicles at excitatory synapses and depress motoneuron activity in vivo.

2015-05-01

[Neuropharmacology 92 , 69-79, (2015)]

Activation of CB2 receptor is required for the therapeutic effect of ABHD6 inhibition in experimental autoimmune encephalomyelitis.

2015-12-01

[Neuropharmacology 99 , 196-209, (2015)]

Cannabinoid receptor 1 inhibition improves the intestinal microcirculation in experimental endotoxemia.

2014-01-01

[Clin. Hemorheol. Microcirc. 58(2) , 333-42, (2014)]

Cannabinoid-induced actomyosin contractility shapes neuronal morphology and growth.

2014-01-01

[Elife 3 , e03159, (2014)]

Ligand activation of cannabinoid receptors attenuates hypertrophy of neonatal rat cardiomyocytes.

2014-11-01

[J. Cardiovasc. Pharmacol. 64(5) , 420-30, (2014)]

More Articles...